Compare Humana Inc (HUM) vs UiPath Inc (PATH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Humana Inc vs UiPath Inc — how do they compare? Humana Inc trades at $433 (market cap $46.49B), while UiPath Inc trades at $13.5 (market cap $6.91B). The key difference: Humana Inc is far larger — about 6.7× UiPath Inc's market cap, and Humana Inc pays a 0.91% dividend while UiPath Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Humana Inc for 51 Days and UiPath Inc for 139 Days on average.
| HUM | PATH | |
|---|---|---|
Market Cap | $46.49B | $6.91B |
Volume | 2,567,704 | 34,321,250 |
Sector | Health | Technology |
52-Week High | $409.85 | $19.29 |
52-Week Low | $163.67 | $9.38 |
Typical Hold Time | 51 Days | 139 Days |
Enterprise Value | $53.84B | $5.70B |
Dividend Yield | 0.91% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Humana (HUM) trades at $436.00, up 9.96% in the last 24 hours, with a bullish technical signal and strong earnings beats in recent quarters. Revenue has grown to $129.66 billion in 2025, though net income margin compressed to 0.88%. Analyst consensus is a buy with a $457.05 price target, and recent news highlights a Barclays upgrade and dividend declaration.
The outlook is positive given earnings momentum and institutional interest, but risks include margin pressure and regulatory scrutiny. Upside potential exists if the company maintains enrollment growth and cost controls, though investors should monitor Medicare Advantage plan changes and competitive dynamics.
UiPath (PATH) trades at $13.45, up 2.87% today, showing technical bullish momentum despite mixed earnings. The company demonstrates strong revenue growth from $1.43B in 2025 to projected $1.7B in 2026, with net income turning positive at $362M. Recent partnerships with Snowflake and BDO highlight strategic expansion in AI orchestration, while analyst consensus remains cautious with 67% hold ratings.
PATH offers growth potential through AI automation leadership but faces execution risks amid competitive pressures. The stock trades below consensus target of $15.13, suggesting 12% upside if guidance is met. Key risks include pricing pressure and integration challenges with new partnerships.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Humana Inc
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →About UiPath Inc
UiPath Inc creates an end-to-end platform that provides automation with user emulation at its core. Its platform is built to be used by employees throughout a company and to address a wide variety of use cases, from simple tasks to long-running, complex business processes. It generates revenue from the sale of licenses for its proprietary software, maintenance and support, and professional services. It generates a majority of the revenues from the US, followed by Romania and the rest of the world.
Read more on PATH →
